The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Kisqali phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in early breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

An interim analysis of NATALEE, a phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer at risk of recurrence demonstrated positive topline results.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Medicaid expansion may improve cancer care and survival for people with HR-negative, HER2-positive breast cancer

New research published in the Journal of the National Comprehensive Cancer Network found that people with newly-diagnosed hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer were more likely to receive timely, guideline-concordant treatment, and have longer survival in states that participate in Medicaid expansion under the Affordable Care Act.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account